Halozyme
S&P 400
$107.20
+0.19%
Delayed · cached 15 min
Fair value analysis
HALO
Halozyme
$107.20
Close used for this calculation
$71.33Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
57/100
Quality radar
Consensus fair value
$71.33
Above FV▼ -33.5% against the close used
Model range $51.20 – $103.36
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear$51.20Fair value$71.33Bull$103.36
FairClose
52-week traded range
52W low $61.6352W high $110.76
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading above the consensus fair value
Halozyme closed at $107.20, 50.3% above the consensus fair value of $71.33 drawn from 6 valuation models.
Financial DNA score 57/100 — Good. P/E of 41.9x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
$103.36
-3.6%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=9%, r=10%, tg=3%, n=10yr
P/E Fair Value
$51.20
-52.2%
EPS × 20x (sector P/E)
EPS=2.56, Sector P/E=20x
Peter Lynch (PEG)
$76.80
-28.4%
EPS × Growth% (PEG = 1 is fair)
EPS=2.56, g=30%
EV/EBITDA
$53.63
-50.0%
(EBITDA × 18x − Net Debt) ÷ Shares
EBITDA=480.4M
Reverse DCF
$107.20
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 17.1% | Historical: 33.6%
Margin of Safety
$57.96
-45.9%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=77.28, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.